Medicus Pharma CFO granted 100,000 stock options

Medicus Pharma Ltd. reported that President and CFO Carolyn F. Bonner received a grant of stock options as equity compensation.

Rhea-AI Filing Summary

Medicus Pharma Ltd. reported that President and CFO Carolyn F. Bonner received a grant of stock options as equity compensation. She was awarded options for 100,000 Common Shares at an exercise price of $0.50 per share, giving her the right to buy shares at that price in the future.

The options become exercisable on March 26, 2027 and expire on March 27, 2031. Following this grant, Bonner holds stock options covering 100,000 shares. This is an acquisition of derivative securities, not an open‑market purchase or sale of the company’s stock.

Insider Trade Summary

Grant/Award: 100,000 shares

Grant/Award 1 txn

Insider Bonner Carolyn F.

Role President and CFO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	100,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 100,000 contracts (Direct)

Key Figures

Options granted: 100,000 options Exercise price: $0.50 per share Underlying shares: 100,000 Common Shares +3 more

6 metrics

Options granted 100,000 options Stock Option (right to buy) granted to President and CFO

Exercise price $0.50 per share Conversion or exercise price of the stock options

Underlying shares 100,000 Common Shares Shares subject to the stock options

Shares following transaction 100,000 options Total derivative securities beneficially owned after grant

Exercise date March 26, 2027 Date options become exercisable

Expiration date March 27, 2031 Date options expire if not exercised

Key Terms

Stock Option (right to buy), grant/award acquisition, Common Shares, exercise price, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

Common Shares financial

"underlying_security_title: Common Shares"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

exercise price financial

"conversion_or_exercise_price: 0.5000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

derivative securities financial

"derivativeTransactionCount: 1"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Medicus Pharma (MDCX) report for Carolyn F. Bonner?

Medicus Pharma reported that President and CFO Carolyn F. Bonner received a grant of stock options for 100,000 Common Shares. These options are a form of equity compensation rather than an open‑market purchase or sale of existing shares.

What are the key terms of Carolyn Bonner’s stock options at Medicus Pharma (MDCX)?

Carolyn Bonner’s options cover 100,000 Common Shares with an exercise price of $0.50 per share. They become exercisable on March 26, 2027 and will expire on March 27, 2031 if not exercised.

Does the Form 4 for Medicus Pharma (MDCX) show any stock being bought or sold on the market?

No market trades are shown. The Form 4 reports a grant/award acquisition of stock options to the President and CFO. This is derivative compensation, not a direct buy or sell of Medicus Pharma’s Common Shares in the open market.

How many Medicus Pharma (MDCX) options does Carolyn Bonner hold after this grant?

After the reported transaction, Carolyn Bonner holds stock options covering 100,000 shares of Medicus Pharma Common Shares. This total reflects the options reported as beneficially owned following the grant on the Form 4.

What type of security was granted to the Medicus Pharma (MDCX) CFO?

The security granted was a Stock Option (right to buy) linked to Common Shares. Each option allows the CFO to purchase one Common Share at $0.50, subject to the specified exercise and expiration dates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/01/2026 - 07:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bonner Carolyn F.

(Last) (First) (Middle)

300 CONSHOHOCKEN STATE ROAD

SUITE 200

(Street)

W.CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.5	03/30/2026		A		100,000		03/26/2027	03/27/2031	Common Shares	100,000	$0	100,000	D

Explanation of Responses:

	/s/ Raza Bokhari, as Attorney-in-Fact, for Carolyn F. Bonner	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)